- Research article
- Open Access
Down-regulation of the alpha-2C adrenergic receptor: involvement of a serine/threonine motif in the third cytoplasmic loop
© Deupree et al; licensee BioMed Central Ltd. 2002
- Received: 29 December 2001
- Accepted: 02 April 2002
- Published: 02 April 2002
The mechanisms by which alpha-2 adrenergic receptors are down-regulated following chronic exposure to agonist are not well understood. Interestingly, the human alpha-2C receptor does not down-regulate, whereas the opossum alpha-2C receptor does down-regulate. A comparison of the amino acid sequence of the third intracellular loop of these two receptors shows that the opossum alpha-2C receptor contains a potential G protein-coupled receptor kinase (GRK)phosphorylation motif (EESSTSE) with four hydroxyl residues, whereas the human alpha-2C receptor motif only contains two hydroxyl residues (DESSAAAAE). Because a similar acidic serine-rich motif (EESSSSD) in the human alpha-2 adrenergic receptor has been demonstrated to be phosphorylated by GRK and all four serines are required for desensitization of the receptor, we sought to determine whether the EESSTSE sequence was involved in the down-regulation of the alpha-2C adrenergic receptor.
Site-directed mutagenesis was used to mutate the opossum alpha-2C receptor to SSVA and AAVA in place of the SSTS wild-type sequence. Down-regulation experiments on CHO cells transfected with the receptors demonstrated that neither of the mutated receptors down-regulated following 24 h exposure to norepinephrine, whereas the wild-type receptor down-regulated to 65 ± 10% of the control.
These results indicate that a motif with four hydroxyl amino acid residues in an acidic environment is important for down-regulation of the opossum alpha-2C adrenergic receptor. Because these are potential GRK phosphorylation sites, we suggest that GRK phosphorylation may be involved in alpha-2C adrenergic receptor down-regulation.
- Adrenergic Receptor
- Intracellular Loop
- Saturation Experiment
- Hydroxyl Residue
- NaPO4 Buffer
Prolonged or repeated agonist stimulation of G protein-coupled receptors frequently causes a reduction in the response to the agonist . Short-term agonist exposure results in desensitization that is characterized by a rapid (minutes) and reversible uncoupling of the receptor from the G protein followed by sequestration and/or internalization of receptors from the cell surface. Down-regulation occurs after prolonged agonist treatment (hours to days), resulting in a loss of receptor binding sites [2–4]. The processes involved in homologous desensitization have been extensively investigated for the beta-2 adrenergic receptor, which is the prototypical G protein-coupled receptor. Initial uncoupling of the beta-2 receptor from the G protein after agonist binding is mediated by phosphorylation by G protein-coupled receptor kinase (GRK) of specific residues in the carboxyl tail of the receptor. The phosphorylated beta-2 receptor enhances the binding of beta-arrestin, which not only uncouples the receptor from the signal transduction process but also serves as an adapter protein that mediates entry into the internalization pathway , as well as serving as a platform for additional signaling pathways . The mechanisms of beta-2 adrenergic receptor down-regulation appear to involve both an increase in the rate of degradation of the receptor as well as a decrease in the levels of beta receptor mRNA . Down-regulation of the beta-2 receptor is, in part, due to trafficking of the beta-2 receptor to lysosomes via the clathrin-coated pit endosomal pathway [8, 9].
The alpha-2 adrenergic receptors also undergo agonist-induced desensitization and down-regulation. Desensitization occurs both in cell culture systems [10–12] and in the intact animal [13, 14]. In general the mechanisms of desensitization for the alpha-2 adrenergic receptors appear to be similar to those for the beta-2 receptor. There are three subtypes of the alpha-2 adrenergic receptor: alpha-2A; alpha-2B; and alpha-2C . The human alpha-2A subtype undergoes phosphorylation and short-term desensitization [11, 12], whereas the human alpha-2C subtype is not phosphorylated  and does not desensitize . The human alpha-2C subtype, however, does undergo arrestin-dependent internalization . Many studies [11, 18], including those from our laboratory [10, 19, 20], have demonstrated agonist-induced down-regulation of alpha-2 receptors, although much less is known about the specific mechanisms for down-regulation as compared to the beta-2 receptor. In contrast to alpha-2A and alpha-2B adrenergic receptors from several species, the human alpha-2C receptor does not appear to down-regulate in response to agonist treatment in transfected cell culture systems . By contrast, the opossum alpha-2C receptor in the OK cell line does down-regulate in response to norepinephrine [19, 20]. The reason for this difference is the focus of the current studies.
Sequence of the opossum alpha-2C adrenergic receptor
In the process of confirming the mutations, we also completely re-sequenced the wild-type clone and found several differences from the originally published sequence (GenBank #U04310 ). The corrected sequence differs from the original in 19 bases, which results in 11 amino acid residue changes as detailed in Figure 2. The sequence has been corrected in Genbank.
Characterization of mutated receptors
Affinity (Kd) and density (Bmax) of mutated alpha-2C adrenergic receptors expressed in CHO cells.
Bmax, fmol/mg protein
0.113 ± 0.008
372 ± 81
SSVA clone #1
0.105 ± 0.005
357 ± 103
SSVA clone #2
0.088 ± 0.009
90 ± 31
AAVA clone #1
0.118 ± 0.012
327 ± 105
AAVA clone #2
0.071 ± 0.009
39 ± 18
Affinity of norepinephrine for the mutated alpha-2C adrenergic receptors expressed in CHO cells.
184 ± 9
90 ± 4*
71 ± 5*
All three alpha-2 adrenergic receptor subtypes from nearly all species that have been tested undergo agonist-induced down-regulation [24, 25]. Interestingly, we have shown that the potency of norepinephrine to produce down-regulation differs among alpha-2 receptor subtypes [19, 24]. The concentration of norepinephrine required to produce half-maximal down-regulation is approximately 2 μM for the alpha-2A receptor. In contrast, norepinephrine is more potent at down-regulating the alpha-2B and alpha-2C subtypes, with a concentration of only 70 nM required to produce half-maximal down-regulation. This difference in potency appears to be a characteristic of the receptor protein itself, because the cellular environment in which a particular subtype is expressed does not affect the potency of norepinephrine to produce down-regulation.
The human alpha-2C receptor is somewhat unique among the alpha-2 receptors in that it does not appear to undergo agonist-induced down-regulation . The human alpha-2A adrenergic receptor, which does undergo down-regulation, has an acidic serine motif (EESSSSD) in the third intracellular loop. Sequentially mutating each of the four serines to alanine decreased the phosphorylation of the receptor by approximately 25% for each serine, and mutating either the first two or the last two serines to alanines prevented agonist-induced desensitization, but not agonist-induced sequestration/internalization . The influence of mutations in this motif on down-regulation has not been investigated. The human alpha-2C receptor, by contrast, has a DESSAAAE sequence in the same region [Figure 2; ]. Thus, it is possible that the lack of desensitization and perhaps also down-regulation of the human alpha-2C receptor is due to the fact that there are only two hydroxyl residues in the DESSAAAE motif rather than the four hydroxyl residues in the alpha-2A EESSSSD motif.
The opossum alpha-2C adrenergic receptor has a EESSTSE acidic serine/threonine motif in the third intracellular loop (Figures 1 and 2), which could be a substrate for GRK based on the EESSSSD motif of the alpha-2A subtype. Thus, we postulated that the lack of down-regulation in the human alpha-2C subtype is related to having only two rather than four serines in the motif, and that mutating the threonine and serine residues at the end of the opossum EESSTSE motif to valine and alanine residues to give EESSVAE might prevent down-regulation of the opossum alpha-2C receptor. Consistent with this prediction, treatment with 0.3 μM norepinephrine for 24 h failed to down-regulate the receptor containing the motif mutated to EESSVAE, although the wild-type receptor with the EESSTSE motif was down-regulated by 35%.
The inhibition data indicate that the affinity of norepinephrine for the receptors containing the mutations is slightly higher than for the wild-type. The affinity of norepinephrine for the mutated receptor lacking two of the hydroxyl residues was approximately twice as high as the wild-type. The elimination of the remaining two hydroxyl residues did not have any additional effect on the affinity of norepinephrine. These data eliminate the possibility that the lack of down-regulation in cells containing the mutated receptors is a consequence of the mutants having a lower affinity for norepinephrine than the wild-type.
The elimination of the terminal two hydroxyl amino acid residues in the EESSTSE motif is sufficient to prevent down-regulation of the opossum alpha-2C adrenergic receptor. Similarly, mutation of only two serine residues in the human alpha-2A receptor resulted in a loss of desensitization . Because the EESSSSE motif in the human alpha-2A receptor is a known GRK substrate, and because eliminating two potential phosphorylation sites prevents down-reguation, phosphorylation of the opossum alpha-2C receptor may be important in the mechanism of down-regulation of this receptor. By contrast, a deletion of twelve residues of the human alpha-2A receptor (293–304) which includes the EESSSSE motif did not appear to prevent agonist-induced down-regulation . Thus a phosphorylation pathway may not be involved in agonist-induced down-regulation of the alpha-2A adrenergic receptor.
G protein-coupled receptors with four hydroxyl amino acid residues in a acid environment.
cAMP class E
A motif with four hydroxyl amino acid residues in an acidic environment appears to be important for down-regulation of the alpha-2C adrenergic receptor. The human alpha-2C receptor, which has a DESSAAAE motif with only two hydroxyl residues, does not undergo down-regulation. Modification of the EESSTSE to EESSVAE was sufficient to prevent down-regulation of the opossum alpha-2C adrenergic receptor. Because these are potential GRK phosphorylation sites, our data further suggest that GRK phosphorylation may be involved in down-regulation of the alpha-2C adrenergic receptor.
Restriction enzymes were purchased from New England Biolabs (Boston, MA). Norepinephrine and other chemicals were from Sigma (St. Louis, MO).
Mutations of the opossum alpha-2C adrenergic receptor cDNA in pRc/CMV vector described previously  was accomplished using the QuickChange™ Site Directed Mutagenesis Kit (Stratagene, LaJolla, CA). The SSTS sequence in the third cytoplasmic loop (amino acid residues 309–312; Figures 1 and 2) was mutated to SSVA using forward and reverse primers with the following sequences (the bases introducing the mutation are underlined), which also introduced a new restriction site: GAACTGGAGGAGAGTAGCGTGGCT GAGAACCGGCGCAGGAGGC and GCCTCCTGCGCCGGTTCTCAGCCAC GCTACTCTCCTCCAGTTC, respectively. To screen for the presence of the mutation, the alpha-2 adrenergic receptor insert was cut from the vector using Hind III (895) and EcoR1 (1841) and cut with Ddel. In a similar manner a further AAVA mutation was prepared from SSVA using GACATCGAACTGGAGGAGGCCGCA GTGGCTGAGAACCGGCGC and GCGCCGGTTCTCAGCCACTGCGGCC TCCTCCAGTTCGATGTC forward and reverse primers, respectively. The presence of the second mutation was determined using the AlwNi. To further confirm the sequence, the entire cDNA for the insert was sequenced for each mutation.
CHO-K1 cells (American Type Culture Collection) were maintained in Ham's F-12 medium (GIBCO) with 10% fetal bovine serum (GIBCO 26140-079) in 95 % air/5% CO2 at 37°C in a humid atmosphere. Wild-type and mutated receptors in the pRc/CMW vector were transfected into CHO-K1 cells using calcium phosphate precipitation technique as described previously . Stable transfectants were selected with 500 μg/ml G-418 (Geneticin; Life Technologies) and screened by intact cell binding using [3H]rauwolscine as previously described .
The cells were plated at a density of 2 × 105 cells/ml in 150-mm culture dishes with 20 ml of growth media and allowed to grow for four days to near confluence. The medium was replaced with fresh medium lacking G-418. Twenty-four hours later, either 2 μl of 3 mM norepinephrine in 5 mM HCl or just 2 μl of 5 mM HCl (vehicle control) was added to each of the plates. Cells were harvested 24 h after adding norepinephrine or vehicle. The medium was removed and the cells were rinsed with 10 ml of cold phosphate-buffered saline (PBS) containing 5 mM EGTA, pH 7.4. Another 10 ml of PBS was added to the plate and the cells were scraped off the plate using a rubber policeman. The plate was rinsed once with 10 ml of PBS. The scraped cells were centrifuged at 2000 × g for 5 min at 4°C, the supernatant was discarded, and the pellet was stored at -80°C until assayed. We used 300 nM norepinephrine in the down-regulation studies because we have previously shown that this concentration induces maximal down-regulation for the wild-type alpha-2C subtype [20, 24].
Pellets were homogenized in 12 ml of ice-cold 50 mM Tris HCl buffer (pH 8.0) with a Tissumizer (Tekmar, Cincinnati, OH) for 20 sec at 75% of the maximum speed and the suspension was centrifuged at 47,000 × g for 10 min at 4°C. This step was repeated a second time. For saturation experiments, the resulting pellet (a crude particulate membrane fraction) was resuspended in 200 volumes of 25 mM NaPO4 buffer (pH 7.4) and re-homogenized for use in the radioligand binding assay. For down-regulation experiments the cells were re-homogenized in 5 ml of 25 mM NaPO4 buffer (pH 7.4).
For saturation experiments, duplicate tubes were prepared containing 970 μl of tissue and 20 μl of [3H]rauwolscine at six concentrations, with final concentrations from approximately 6 pM to 0.6 nM. Nonspecific binding was determined using a final concentration of 200 μM (-)-norepinephrine. For competition experiments, duplicate tubes were prepared containing 970 μl of tissue, 10 μl of norepinephrine at various concentrations, and 20 μl of [3H]rauwolscine (81.5 Ci/mmol, NEN-Dupont, Boston, MA) at a single concentration of 0.12 nM, which is approximately the Kd value. Twelve appropriately spaced concentrations of norepinephrine were used in each competition experiment. The extent of down-regulation was determined using a single concentration of [3H]rauwolscine (0.40 nM; about 3 times the Kd value). We have previously shown that norepinephrine pretreatment does not alter the radioligand Kd of the opossum alpha-2C adrenergic receptor [20, 24], thus making it possible to estimate the receptor density with a single concentration of radioligand. Total binding was determined in triplicate and nonspecific binding in duplicate for each of the three dishes for each condition. All assays were incubated at room temperature for 60 min. Membrane suspensions were filtered through Whatman GF/B glass fiber filters with a 48-sample Brandel cell harvester (Biomedical Research and Development, Gaithersburg, MD). Filters and tubes were washed three times with ice-cold 50 mM Tris HCl buffer (pH 8.0). Radioactivity was determined by liquid scintillation photometry. Protein concentrations were determined using the Bio-Rad Protein Assay (Bio-Rad, CA) based on the Bradford method , with bovine serum albumin as the standard.
Bmax (receptor density) and Kd (radioligand affinity) values were determined from the analyses of saturation experiments utilizing nonlinear regression with Prism 3 (GraphPad, San Diego, CA). Bmax and Kd values are given as arithmetic and geometric means, respectively. Competition binding data were also analyzed with Prism 3 to determine the IC50 values based on the single-site model and slope based on the variable slope model. Ki values were calculated from the IC50 values , and are presented as geometric means. The statistical analysis of the down-regulation data was conducted using a two-tailed paired t-test of the mean of the duplicate assays for each dish of cells incubated in the presence of norepinephrine as compared to control cells.
- Chuang TT, Iacovelli L, Sallese M, De Blasi A: G protein-coupled receptors: Heterologous regulation of homologous desensitization and its implications. Trends Pharmacol Sci. 1996, 17: 416-421. 10.1016/S0165-6147(96)10048-1.View ArticlePubMedGoogle Scholar
- Hein L, Kobilka BK: Adrenergic receptor signal transduction and regulation. Neuropharmacology. 1995, 34: 357-366. 10.1016/0028-3908(95)00018-2.View ArticlePubMedGoogle Scholar
- Toews ML, Shreve PE, Bylund DB: Regulation of adrenergic receptors. In Signaling Mechanisms in Secretory and Immune Cells. Edited by: Martinez JR, Edwards BS, Seagrave JC. 1991, San Francisco: San Francisco Press, 1-17.Google Scholar
- Tsao P, von Zastrow M: Downregulation of G protein-coupled receptors. Curr Opin Neurobiol. 2000, 10: 365-369. 10.1016/S0959-4388(00)00096-9.View ArticlePubMedGoogle Scholar
- Ferguson SSG, Downey WE, Colapietro AM, Barak LS, Ménard L, Caron MG: Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science. 1996, 271: 363-366.View ArticlePubMedGoogle Scholar
- Miller WE, Lefkowitz RJ: Expanding roles for beta-arrestins as scaffolds and adapters in GPCR signaling and. Curr Opin Cell Biol. 2001, 13: 139-145. 10.1016/S0955-0674(00)00190-3.View ArticlePubMedGoogle Scholar
- Bouvier M, Collins S, O'Dowd BF, Campbell PT, de-Blasi A, Kobilka BK, et al: Two distinct pathways for cAMP-mediated down-regulation of the beta-2 adrenergic receptor: Phosphorylation of the receptor and regulation of its mRNA level. J Biol Chem. 1989, 264: 16786-16792.PubMedGoogle Scholar
- Gagnon AW, Kallal L, Benovic JL: Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta-2 adrenergic receptor. J Biol Chem. 1998, 273: 6976-6981. 10.1074/jbc.273.12.6976.View ArticlePubMedGoogle Scholar
- Kallal L, Gagnon AW, Penn RB, Benovic JL: Visualization of agonist-induced sequestration and down-regulation of a green fluorescent protein-tagged β2-adrenergic receptor. J Biol Chem. 1998, 273: 322-328. 10.1074/jbc.273.1.322.View ArticlePubMedGoogle Scholar
- Jones SB, Leone SL, Bylund DB: Desensitization of the alpha-2 adrenergic receptor in HT29 and opossum kidney cell lines. J Pharmacol Exp Ther. 1990, 254: 294-300.PubMedGoogle Scholar
- Eason MG, Liggett SB: Subtype-selective desensitization of alpha-2 adrenergic receptors. Different mechanisms control short and long-term agonist-promoted desensitization of alpha 2C10, alpha 2C4, and alpha 2C2. J Biol Chem. 1992, 267: 25473-25479.PubMedGoogle Scholar
- Eason MG, Moreira SP, Liggett SB: Four consecutive serines in the third intracellular loop are the sites for β-adrenergic receptor kinase-mediated phosphorylation and desensitization of the alpha-2A adrenergic receptor. J Biol Chem. 1995, 270: 4681-4688. 10.1074/jbc.270.9.4681.View ArticlePubMedGoogle Scholar
- Hayashi Y, Guo TZ, Maze M: Desensitization to the behavioral effects of alpha-2 adrenergic agonists in rats. Anesthesiology. 1995, 82: 954-962. 10.1097/00000542-199504000-00019.View ArticlePubMedGoogle Scholar
- Reid K, Hayashi Y, Hsu J, Maguire PA, Rabin BC, Guo TZ, et al: Chronic treatment with dexmedetomidine desensitizes alpha-2 adrenergic signal transduction. Pharmacol Biochem Behav. 1997, 57: 63-71. 10.1016/S0091-3057(96)00127-X.View ArticlePubMedGoogle Scholar
- Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, et al: IV. International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol Rev. 1994, 46: 121-136.PubMedGoogle Scholar
- Jewell-Motz EA, Liggett SB: G protein-coupled receptor kinase specificity for phosphorylation and desensitization of alpha-2 adrenergic receptor subtypes. J Biol Chem. 1996, 271: 18082-18087. 10.1074/jbc.271.30.18082.View ArticlePubMedGoogle Scholar
- DeGraff JL, Gagnon AW, Benovic JL, Orsini MJ: Role of arrestins in endocytosis and signaling of alpha-2 adrenergic receptor subtypes. J Biol Chem. 1999, 274: 11253-11259. 10.1074/jbc.274.16.11253.View ArticlePubMedGoogle Scholar
- Thomas JM, Hoffman BB: Agonist-induced down-regulation of muscarinic cholinergic and alpha-2 adrenergic receptors after inactivation of Ni by pertussis toxin. Endocrinology. 1986, 119: 1305-1314.View ArticlePubMedGoogle Scholar
- Pleus RC, Shreve PE, Toews ML, Bylund DB: Down-regulation of alpha-2 adrenoceptor subtypes. Eur J Pharmacol. 1993, 244: 181-185. 10.1016/0922-4106(93)90024-4.View ArticlePubMedGoogle Scholar
- Shreve PE, Toews ML, Bylund DB: Alpha-2A and alpha-2C adrenergic subtypes are differentially down-regulated by norepinephrine. Eur J Pharmacol. 1991, 207: 275-276. 10.1016/0922-4106(91)90042-G.View ArticlePubMedGoogle Scholar
- Blaxall HS, Cerutis DR, Mass NA, Iversen LJ, Bylund DB: Cloning and expression of the alpha-2C adrenergic receptor from the OK cell line. Mol Pharmacol. 1994, 45: 176-181.PubMedGoogle Scholar
- Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB: A four amino acid deletion polymorphism in the third intracellular loop of the human alpha-2C adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 2000, 275: 23059-23064. 10.1074/jbc.M000796200.View ArticlePubMedGoogle Scholar
- Deupree JD, Hinton KA, Cerutis DR, Bylund DB: Buffers differentially alter the binding of [3H]rauwolscine and [3H]RX821002 to the alpha-2 adrenergic receptor subtypes. Pharmacol Exp Ther. 1996, 278: 1215-1227.Google Scholar
- Cerutis DR, Deupree JD, Heck DA, Zhu S-J, Toews ML, Bylund DB: Differential regulation of alpha-2 adrenergic receptor subtypes by norepinephrine and buffers. In Alpha-2 Adrenergic Receptors: Structure, Function and Therapeutic Implications. Edited by: Lanier SM, Limbird LE. 1996, London: Gorden and Breach, 103-112.Google Scholar
- Saunders C, Limbird LE: Localization and trafficking of alpha-2 adrenergic receptor subtypes in cells and tissues. Pharmacol Ther. 1999, 84: 193-205. 10.1016/S0163-7258(99)00032-7.View ArticlePubMedGoogle Scholar
- Jewell-Motz EA, Donnelly ET, Eason MG, Liggett SB: Role of the amino terminus of the third intracellular loops in agonist-promoted downregulation of the alpha-2A adrenergic receptor. Biochemistry. 1997, 36: 8858-8863. 10.1021/bi970487x.View ArticlePubMedGoogle Scholar
- Onorato JJ, Palczewski K, Regan JW, Caron MG, Lefkowitz RJ, Benovic JL: Role of acidic amino acids in peptide substrates of the beta-adrenergic receptor kinase and rhodopsin kinase. Biochemistry. 1991, 30: 5118-5125.View ArticlePubMedGoogle Scholar
- Small KM, Brown KM, Forbes SL, Liggett SB: Polymorphic deletion of three intracellular acidic residues of the alpha-2B adrenergic receptor decreases GRK-mediated phosphorylation and desensitization. J. Biol Chem. 2001, 276: 4917-4922. 10.1074/jbc.M008118200.View ArticlePubMedGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1006/abio.1976.9999.View ArticlePubMedGoogle Scholar
- Cheng Y-C, Prusoff WH: Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973, 22: 3099-3108. 10.1016/0006-2952(73)90196-2.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.